Evidence map›Paper›PMID 35325079›Full record

ArticleBrain : a journal of neurology2022

Progression of cerebral white matter hyperintensities is related to leucocyte gene expression.

Glen C Jickling, Bradley P Ander, Xinhua Zhan, Boryana Stamova, Heather Hull, Charles DeCarli, Frank R Sharp

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Promoter hypomethylation ofFrontiers in genetics · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Cerebral amyloid angiopathy and the immune system.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Glen C JicklingDepartment of Neurology, University of California Davis School of Medicine, Sacramento, CA, USA.ORCID 0000-0003-3543-0820
Bradley P AnderDepartment of Neurology, University of California Davis School of Medicine, Sacramento, CA, USA.
Xinhua ZhanDepartment of Neurology, University of California Davis School of Medicine, Sacramento, CA, USA.
Boryana StamovaDepartment of Neurology, University of California Davis School of Medicine, Sacramento, CA, USA.
Heather HullDepartment of Neurology, University of California Davis School of Medicine, Sacramento, CA, USA.
Charles DeCarliDepartment of Neurology, University of California Davis School of Medicine, Sacramento, CA, USA.
Frank R SharpDepartment of Neurology, University of California Davis School of Medicine, Sacramento, CA, USA.
University of California, Davis · USUniversity of Alberta · CA

Funding

NRF2 Anti-Oxidant Systems and White Matter HyperintensitiesR01AG042292 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DECARLI, CHARLES, SHARP, FRANK R · 2013 to 2017
$3.0M
NIA NIH HHS R01 AG042292
6 · The paper itself

Abstract

Cerebral white matter hyperintensities are an important contributor to ageing brain pathology. Progression in white matter hyperintensity volume is associated with cognitive decline and gait impairment. Understanding the factors associated with white matter hyperintensity progression provides insight into pathogenesis and may identify novel treatment targets to improve cognitive health. We postulated that the immune system interaction with cerebral vessels and tissue may be associated with disease progression, and thus evaluated the relationship of blood leucocyte gene expression to progression of cerebral white matter hyperintensities. A brain MRI was obtained at baseline in 166 patients assessed for a cognitive complaint, and then repeated at regular intervals over a median of 5.9 years (interquartile range 3.5-8.2 years). White matter hyperintensity volumes were measured by semi-automated segmentation and percentage change in white matter hyperintensity per year calculated. A venous blood sample obtained at baseline was used to measure whole-genome expression by RNA sequencing. The relationship between change in white matter hyperintensity volumes over time and baseline leucocyte gene expression was analysed. The mean age was 77.8 (SD 7.5) years and 60.2% of participants were female. The median white matter hyperintensity volume was 13.4 ml (SD 17.4 ml). The mean change in white matter hyperintensity volume was 12% per year. Patients were divided in quartiles by percentage change in white matter hyperintensity volume, which was: -3.5% per year in quartile 1, 7.4% per year in quartile 2, 11.7% in quartile 3 and 33.6% per year in quartile 4. There were 148 genes associated with changing white matter hyperintensity volumes over time (P < 0.05 r > |0.2|). Genes and pathways identified have roles in endothelial dysfunction, extracellular matrix remodelling, altered remyelination, inflammation and response to ischaemia. ADAM8, CFD, EPHB4, FPR2, Wnt-B-catenin, focal adhesion kinase and SIGLEC1 were among the identified genes. The progression of white matter hyperintensity volumes over time is associated with genes involved in endothelial dysfunction, extracellular matrix remodelling, altered remyelination, inflammation and response to ischaemia. Further studies are needed to evaluate the role of peripheral inflammation in relation to rate of white matter hyperintensity progression and the contribution to cognitive decline.

Indexed as

Cognitive DysfunctionLeukoaraiosisWhite MatterADAM ProteinsAgedAged, 80 and overDisease ProgressionFemaleGene ExpressionHumansInflammationLeukocytesMagnetic Resonance ImagingMaleMembrane ProteinsADAM8 protein, humanADAM ProteinsMembrane Proteinscognitive declinegene expressionleucocytemRNAwhite matter hyperintensity

Identifiers

PMID35325079
PMCPMC10233292
OpenAlexW4221091248

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.